Summit Therapeutics clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 2 with minor changes only.

1. Minor

   Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

   Enrollment closed, study ongoing

   Summit Therapeutics·Phase 3· NCT05899608· Registry history of NCT05899608 on ClinicalTrials.gov (opens the registry)

   Oct 8, 2026

2. Minor

   HARMONi-GI3 · Ivonescimab or Bevacizumab Combined With FOLFOX…HARMONi-GI3 · Ivonescimab or Bevacizumab Combined With FOLFOX · Metastatic Colorectal Cancer

   Trial sites expanded: 213 → 236 locations

   Summit Therapeutics·Phase 3· NCT07228832· Registry history of NCT07228832 on ClinicalTrials.gov (opens the registry)

   Oct 6, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.